Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20174736 | 0.95 | S1PR5 (0.35) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL19008468 | 0.94 | MEN1 (0.35) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL20174627 | 0.93 | S1PR5 (0.34) | MEN1KMT2AALDH1A1L3MBTL1KDM4E | |
| SCHEMBL20174623 | 0.91 | MEN1 (0.39) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL20174567 | 0.91 | PDK2 (0.38) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL20174737 | 0.90 | PDK2 (0.36) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL20174602 | 0.90 | PDK2 (0.36) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL20174654 | 0.89 | PDK2 (0.39) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL20174734 | 0.89 | MEN1 (0.38) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL20174637 | 0.89 | PDK2 (0.34) | MAPTALDH1A1HPGDL3MBTL1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738034-B2 | Spiro compound and organic light-emitting device comprising same | LG CHEM, LTD. (KR) | 2020-08-11 | — | — | US | disclosed |
| US-20180141933-A1 | SPIRO COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-05-24 | — | — | US | disclosed |
| US-20180141933-A1 | SPIRO COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738034-B2 | Spiro compound and organic light-emitting device comprising same | CRY1, NR2E3, ERG | MEN1 611/4885KMT2A 1480/4885MAPT 811/4885 |
| US-20180141933-A1 | SPIRO COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | CRY1, NR2E3, ERG | MEN1 611/4885KMT2A 1480/4885MAPT 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.